

100mg

Catalog No: SR144528



Available Sizes

Size: c29h34cln3o



Specifications

CAS No:

casno

Formula:

192703`06`3

Pathway:

Cannabinoid Receptor

Target:

SR144528 is a potent and selective **CB2 receptor** antagonist with a K_i of 0.6 nM. IC50 & Target: K_i : 0.6 nM (CB2 receptor)^[1] **In Vitro:** SR144528 is a potent and selective CB2 receptor antagonist with a K_i of 0.6 nM. SR144528 alone is able to stimulate in a concentration-dependent manner ($EC_{50}=26\pm6$ nM, two experiments) the forskolin-sensitive adenylyl cyclase activity in CHO-CB2 cells with a maximum effect at 1 μ M (4-fold stimulation) whereas at this concentration it has no significant effect on CHO-CB1 cells (15% inhibition)^[1]. Raw 264.7 macrophages supplemented with SR144528 display reduced caspase-3 activity. SR144528 inhibits microsomal acyl-coenzymeA:cholesterol acyltransferase (ACAT) activity in a concentration-dependent manner with an IC_{50} value of 3.6 ± 1.1 μ M. At 10 μ M, SR144528 inhibits ACAT activities $\sim 68\%$ ^[2]. **In Vivo:** No effect on the binding of [³H]-CP 55,940 to its specific sites in the brain is observed after either oral (up to 10 mg/kg) or i.c.v. (10 μ g/animal) administration of SR144528 in mice. The occupancy by SR144528 of the spleen cannabinoid receptor is time-dependent and significant for at least 18 hours after oral administration at 3 mg/kg^[1]. SR144528 does not induce any significant effect on gastrointestinal (GI) motility when given alone. SR144528 does not block but enhances delayedgastric emptying^[3].

Purity / Grade:

476.05

Solubility:

No Development Reported

Alternative Names:

1584



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!